The Melbourne Diabetes Prevention Study (MDPS): Study protocol for a randomized controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Davis Lameloise, Nathalie ^a   Hernan, Andrea ^a   Janus, Edward D ^a,b   Stewart, Elizabeth ^a,c   Carter, Rob ^c   Bennett, Catherine M ^c   O'Reilly, Sharleen ^c   Philpot, Benjamin ^a   Vartiainen, Erkki ^d   Dunbar, James A ^a  

^a Greater Green Triangle University Department of Rural Health   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Intervention; Lifestyle; Prevention; Protocol; Randomized controlled trial; Type 2 diabetes

Indexed keywords

ADULT; AGED; ANTHROPOMETRY; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; EMPOWERMENT; GOAL ATTAINMENT; GROUP THERAPY; HEALTH PROGRAM; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; AUSTRALIA; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; HUMANS; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; SAMPLE SIZE; STATISTICS AS TOPIC;

EID: 84873035518     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-31     Document Type: Article

References (42)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 2004, 27:1047-1053. 10.2337/diacare.27.5.1047, 15111519.
2. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y-H, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011, 378:31-40. 10.1016/S0140-6736(11)60679-X, 21705069, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose).
3. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust 2008, 188:36-40.
4. Vos T, Goss J, Begg S, Mann M. Projection of health care expenditure by disease: a case study from Australia. Background paper for United Nations 2007 World Economic and Social Survey publication 2007, Brisbane: University of Queensland.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. 1370926, 11832527.
6. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350. 10.1056/NEJM200105033441801, 11333990, Finnish Diabetes Prevention Study Group.
7. Li G, Hu Y, Yang W, Jiang Y, Wang J, Xiao J, Hu Z, Pan X, Howard BV, Bennett PH. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract 2002, 58:193-200. 10.1016/S0168-8227(02)00175-4, 12413779.
8. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, DREAM (Diabetes REducation Assessment with ramipril and roseglitazone Medication) Trial Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105. DREAM (Diabetes REducation Assessment with ramipril and roseglitazone Medication) Trial Investigators.
9. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study Group Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679. 10.1016/S0140-6736(06)69701-8, 17098085, Finnish Diabetes Prevention Study Group.
10. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008, 371:1783-1789. 10.1016/S0140-6736(08)60766-7, 18502303.
11. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686. 10.1016/S0140-6736(09)61457-4, 3135022, 19878986.
12. Laatikainen T, Dunbar J, Chapman A, Kilkkinen A, Vartiainen E, Heistaro S, Philpot B, Absetz P, Bunker S, O'Neil A, Reddy P, Best JD, Janus ED. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC Public Health 2007, 7:249. 10.1186/1471-2458-7-249, 2039742, 17877832.
13. Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999, 42:793-801. 10.1007/s001250051229, 10440120.
14. Absetz P, Valve R, Oldenberg B, Heinonen H, Nissinen A, Fogelholm M, Ilvesmaki V, Talja M, Uutela A. Type 2 diabetes prevention in the " Real World" - one-year results of the GOAL implementation trial. Diabetes Care 2007, 30:2465-2470. 10.2337/dc07-0171, 17586741.
15. Baker IDI Heart and Diabetes Institute on behalf of the Australian State and Territory Governments Australian Type 2 Diabetes Risk Assessment Tool, AUSDRISK 2008, Canberra (ACT), Australia: Canberra (ACT), Australia, Department of Health and Ageing, Baker IDI Heart and Diabetes Institute on behalf of the Australian State and Territory Governments.
16. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003, 26:725. 10.2337/diacare.26.3.725, 12610029.
17. Chen L, Magliano DJ, Balkau B, Colagiuri S, Zimmet PZ, Tonkin AM, Mitchell P, Phillips PJ, Shaw JE. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. Med J Aust 2010, 192:197-202.
18. Bandura A. Self-efficacy: The Exercise of Control 1997, USA; Worth Publishers, New York, NY.
19. Schwarzer R. Self-efficacy in the adoption and maintenance of health behaviors: theoretical approaches and a new model. Self-efficacy: Thought Control of Action 1992, 217-242. Washington, DC: Hemisphere.
20. Schwarzer R, Fuchs R. Self efficacy and health behaviors. Predicting Health Behavior: Research and Practice with Social Cognition Models 1996, 163-196. Buckingham, UK: Open University Press, Connor M, Norman P.
21. Bandura A. Social Foundations of Thought and Action: A Social Cognitive Theory 1986, Prentice Hall; Upper Saddle River, NJ, USA.
22. Prochaska JO, Velicer WF. Behavior change: the transtheoretical model of health behavior change. Am J Health Promot 1997, 12:38-48. 10.4278/0890-1171-12.1.38, 10170434.
23. Feste C, Anderson R. Empowerment: from philosophy to practice. Patient Educ Couns 1995, 26:139. 10.1016/0738-3991(95)00730-N, 7494713.
24. Funnell M, Anderson R. Patient empowerment: a look back, a look ahead. Diabetes Educ 2003, 29:454-466. 10.1177/014572170302900310, 12854337.
25. Rappaport J. Terms of empowerment/exemplars of prevention: toward a theory for community psychology. Am J Community Psychol 1987, 15:121-148. 10.1007/BF00919275, 3604997.
26. Oettingen G, Hönig G, Gollwitzer PM. Effective self-regulation of goal attainment. Int J Educ Res 2000, 33:705-732.
27. Oettingen G, Pak H, Schnetter K. Self-regulation of goal-setting: turning free fantasies about the future into binding goals. J Pers Soc Psychol 2001, 80:736-753.
28. Schwarzer R, Renner B. Social-cognitive predictors of health behavior: action self-efficacy and coping self-efficacy. Health Psychol 2000, 19:487-495.
29. Carter R, Vos T, Moodie M, Haby M, Magnus A, Mihalopoulos C. Priority setting in health: origins, description and application of the Australian Assessing Cost-Effectiveness initiative. Expert Rev Pharmacoecon Outcomes Res 2008, 8:593-617. 10.1586/14737167.8.6.593, 20528370.
30. WHO The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988, 41:105-114. 10.1016/0895-4356(88)90084-4, 3335877, WHO.
31. Tolonen H, Kuulasmaa K, Laatikainen T, Wolf H. European Health Risk Monitoring Project. Recommendation for indicators, international collaboration, protocol and manual of operations for chronic disease risk factor surveys Helsinki, Finland: , National Public Health Institute (KTL), http://www.ktl.fi/publications/ehrm/product2/product2.pdf.
32. Levesque CS, Williams GC, Elliot D, Pickering MA, Bodenhamer B, Finley PJ. Validating the theoretical structure of the Treatment Self-Regulation Questionnaire (TSRQ) across three different health behaviors. Health Educ Res 2007, 22:691-702.
33. Renner B, Schwarzer R. Risk and health behaviors: documentation of the Scales of the Research Project " Risk Appraisal Consequences in Korea" (RACK). Risk and Health Behaviors: Documentation of the Scales of the Research Project " Risk Appraisal Consequences in Korea" (RACK) 2005, 1-55. International University Bremen & Freie Universität Berlin, 2.
34. Schwarzer R, Renner B. Health-Specific Self-Efficacy Scales. 2008, 1-21. [Personal Communication].
35. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The Multidimensional Scale of Perceived Social Support. J Pers Assess 1988, 52:30-41.
36. Quality of Life (AQoL) [http://www.aqol.com.au/] URL accessed on 29.01.2013.
37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
38. Webster C, Austin W. Health-related hardiness and the effect of a psycho-educational group on clients' symptoms. J Psychiatr Ment Health Nurs 1999, 6:241-247. 10.1046/j.1365-2850.1999.630241.x, 10633678.
39. Australian Institute of Health and Welfare The Active Australia Survey: a guide and manual for implementation, analysis and reporting 2003, Canberra (ACT), Australia, AIHW, Australian Institute of Health and Welfare.
40. Hodge A, Patterson AJ, Brown WJ, Ireland P, Giles G. The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle-aged women in a study of iron supplementation. Aust N Z J Public Health 2000, 24:576-583. 10.1111/j.1467-842X.2000.tb00520.x, 11215004.
41. Lindstrom J, Neumann A, Sheppard KE, Gilis-Januszewska A, Greaves CJ, Handke U, Pajunen P, Puhl S, Polonen A, Rissanen A, Roden M, Stemper T, Telle-Hjellset V, Tuomilehto J, Velickiene D, Schwarz PE, Acosta T, Adler M, AlKerwi A, Barengo N, Barengo R, Boavida JM, Charlesworth K, Christov V, Claussen B, Cos X, Cosson E, Deceukelier S, Dimitrijevic-Sreckovic V, Djordjevic P. Take action to prevent diabetes-the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 2010, 42(Suppl 1):S37-S55.
42. Paulweber B, Valensi P, Lindstrom J, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J, Sheppard KE, Charlesworth K, Felton AM, Hall M, Rissanen A, Tuomilehto J, Schwarz PE, Roden M, Paulweber M, Stadlmayr A, Kedenko L, Katsilambros N, Makrilakis K, Kamenov Z, Evans P, Gilis-Januszewska A, Lalic K, Jotic A, Djordevic P, Dimitrijevic-Sreckovic V. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010, 42(Suppl 1):S3-S36.